Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy of Onabotulinum Toxin A on Obsessive-Compulsive Traits in a Population of Chronic Migraine Patients.

< BACK TO ARCHIVE


2022 Nov 17


Brain Sci


http://www.ncbi.nlm.nih.gov/pubmed/36421886?dopt=Abstract


12


11

Efficacy of Onabotulinum Toxin A on Obsessive-Compulsive Traits in a Population of Chronic Migraine Patients.

Authors

Efficacy of Onabotulinum Toxin A on Obsessive-Compulsive Traits in a Population of Chronic Migraine Patients.
Viticchi G, Falsetti L, Salvemini S, Bartolini M, Paolucci S, Buratti L, Silvestrini M
Brain Sci. 2022 Nov 17; 12(11).
PMID: 36421886.

Abstract

Drug addiction may play an important role in chronic migraine (CM) with medication-overuse headache (MOH). Psychiatric diseases are associated with CM, but data regarding obsessive-compulsive disorder (OCD) are lacking. We aimed to establish the prevalence of OCD traits in CM patients with MOH and the impact on onabotulinum toxin A (OBT-A) treatment.
Read This Paper